Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19FN4O4 |
| Molecular Weight | 362.3562 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)c2c(cc3c4c2OCN(C)n4cc(c3=O)C(=O)O)F
InChI
InChIKey=BPFYOAJNDMUVBL-UHFFFAOYSA-N
InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)
DescriptionCurator's Comment:: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Curator's Comment:: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05196313-2371-45ad-a6fb-6269f8ef94c5
Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date9.3260159E11 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date9.3260159E11 |
|||
| Curative | Zeniquin Approved UseZeniquin (marbofloxacin) tablets are indicated for the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. Launch Date9.3260159E11 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. | 2004 Dec |
|
| Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. | 2005 Feb |
|
| Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats. | 2005 Sep |
|
| Isolation of methicillin-resistant Staphylococcus aureus from a non-healing abscess in a cat. | 2005 Sep 24 |
|
| [Resistance of mastitis pathogens in northern Germany]. | 2005 Sep-Oct |
|
| Inclusion of marbofloxacin in PMMA orthopaedic cement: an in vitro experimental study. | 2006 |
|
| Simultaneous determination of (fluoro)quinolone antibiotics in kidney, marine products, eggs, and muscle by enzyme-linked immunosorbent assay (ELISA). | 2006 Apr 19 |
|
| Clinical efficacy of intravenous administration of marbofloxacin in a Staphylococcus aureus infection in tissue cages in ponies. | 2006 Dec |
|
| Pharmacokinetic and pharmacodynamic interactions of tolfenamic acid and marbofloxacin in goats. | 2006 Feb |
|
| Pharmacokinetics of marbofloxacin in blue and gold macaws (Ara ararauna). | 2006 Jun |
|
| Comparative pharmacokinetics of marbofloxacin after a single intramuscular administration at two dosages to camels (Camelus dromedarius). | 2006 Jun |
|
| Epidemiology and susceptibility of pathogenic bacteria responsible for upper respiratory tract infections in pet rabbits. | 2006 Jun 15 |
|
| Effect of chronic feline immunodeficiency infection, and efficacy of marbofloxacin treatment, on 'Candidatus Mycoplasma haemominutum' infection. | 2006 Mar |
|
| The pharmacokinetic behaviour of marbofloxacin in Eurasian buzzards (Buteo buteo) after intraosseous administration. | 2006 May |
|
| Multiresidue method for the determination of quinolone antibiotics in bovine raw milk by capillary electrophoresis-tandem mass spectrometry. | 2006 Nov 15 |
|
| Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. | 2006 Nov-Dec |
|
| Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. | 2006 Oct |
|
| Enrofloxacin and marbofloxacin in horses: comparison of pharmacokinetic parameters, use of urinary and metabolite data to estimate first-pass effect and absorbed fraction. | 2006 Oct |
|
| Field evaluation of the efficacy of tolfenamic acid administered in one single preoperative injection for the prevention of postoperative pain in the dog. | 2007 Dec |
|
| Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals. | 2007 Feb 1 |
|
| [Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry]. | 2007 Jul |
|
| Pharmacokinetics of a single intravenous dose of marbofloxacin in adult donkeys. | 2007 Jul 28 |
|
| In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals. | 2007 Jun |
|
| Separation of fifteen quinolones by high performance liquid chromatography: application to pharmaceuticals and ofloxacin determination in urine. | 2007 Jun |
|
| Identification and comparison of marbofloxacin metabolites from the plasma of ball pythons (Python regius) and blue and gold macaws (Ara ararauna). | 2007 Jun |
|
| Microbiological detection of 10 quinolone antibiotic residues and its application to artificially contaminated poultry samples. | 2007 Mar |
|
| Stability of frozen stock solutions of beta-lactam antibiotics, cephalosporins, tetracyclines and quinolones used in antibiotic residue screening and antibiotic susceptibility testing. | 2007 Mar 14 |
|
| Simultaneous determination of trace levels of 10 quinolones in swine, chicken, and shrimp muscle tissues using HPLC with programmable fluorescence detection. | 2007 May 16 |
|
| Single-dose pharmacokinetics of marbofloxacin in Egyptian buffalo (Bubalus bubalis L.) steers. | 2007 May-Jun |
|
| Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. | 2007 Nov |
|
| Multiresidue method for simultaneous determination of quinolone antibacterials in pig kidney samples by liquid chromatography with fluorescence detection. | 2007 Nov 15 |
|
| Susceptibility of Pseudomonas isolates from the ears and skin of dogs to enrofloxacin, marbofloxacin, and ciprofloxacin. | 2007 Nov-Dec |
|
| Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis. | 2007 Nov-Dec |
|
| Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis. | 2007 Oct |
|
| Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic integration of marbofloxacin after subcutaneous administration in goats. | 2007 Sep |
|
| Comparative quantification of the in vitro activity of veterinary fluoroquinolones. | 2007 Sep 20 |
|
| Improved determination of quinolones in milk at their MRL levels using LC-UV, LC-FD, LC-MS and LC-MS/MS and validation in line with regulation 2002/657/EC. | 2008 Apr 14 |
|
| Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS. | 2008 Jul |
|
| Development of an immunochromatography strip for the rapid detection of 12 fluoroquinolones in chicken muscle and liver. | 2008 Jul 23 |
|
| [Multiresidue determination of quinolones in animal and fishery products by HPLC]. | 2008 Jun |
|
| Intraocular pharmacokinetics of intravenously administered marbofloxacin in rabbits with experimentally induced acute endophthalmitis. | 2008 Mar |
|
| Marbofloxacin for the treatment of experimentally induced Mycoplasma haemofelis infection in cats. | 2008 Mar-Apr |
|
| In-line solid-phase extraction preconcentration in capillary electrophoresis-tandem mass spectrometry for the multiresidue detection of quinolones in meat by pressurized liquid extraction. | 2008 May |
|
| Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. | 2008 May 31 |
|
| Tissue distribution of marbofloxacin after 'systemic' administration into the isolated perfused bovine udder. | 2008 Oct |
|
| Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. | 2008 Sep 18 |
|
| Influence of systemic fluoroquinolone administration on the presence of Pasteurella multocida in the upper respiratory tract of clinically healthy calves. | 2008 Sep 22 |
|
| Water-compatible molecularly imprinted polymer for the selective recognition of fluoroquinolone antibiotics in biological samples. | 2009 Jan |
|
| Resolution of tongue lesions caused by Leishmania infantum in a dog treated with the association miltefosine-allopurinol. | 2009 Mar 26 |
|
| Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta). | 2009 Oct |
Patents
Sample Use Guides
1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.
Route of Administration:
Other
MIC50 values of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs were: Staphylococcus intermedius - 0.25 ug/ml, Escherichia coli - 0.03 ug/ml, Proteus mirabilis - 0.06 ug/ml, Beta-hemolytic Streptococcus, (not Group A or Group B) - 1 ug/ml, Streptococcus, Group D enterococcus - 1 ug/ml, Pasteurella multocida - 0.015 ug/ml, Staphylococcus aureus - 0.25 ug/ml, Enterococcus faecalis - 2 ug/ml, Klebsiella pneumoniae - 0.06 ug/ml.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.1310
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
||
|
WHO-VATC |
QJ01MA93
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB11426
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
8X09WU898T
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
69256
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | RxNorm | ||
|
115550-35-1
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
6807
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
MARBOFLOXACIN
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
M7085
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL478120
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
115550-35-1
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
C80640
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
60651
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY | |||
|
SUB08648MIG
Created by
admin on Sat Jun 26 15:31:39 UTC 2021 , Edited by admin on Sat Jun 26 15:31:39 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
